FierceBiotech

Infinity Reports Topline Data from Phase 2 Study of Retaspimycin Hydrochloride, Its Hsp90 Inhibitor, in Patients with Non-Small Cell Lung Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (INFI) today announced topline data from its Phase 2 study of retaspimycin hydrochloride (HCl), a potent and selective heat shock ...
Business Wire

INFINITI climbs 15 places in J.D. Power 2024 U.S. Initial Quality Study, ranks fourth in premium segment

2024 QX80 ranked highest in initial quality in the Large Premium SUV segment NASHVILLE, Tenn.--(BUSINESS WIRE)--INFINITI continues to bring thoughtful hospitality to every aspect of the client ...
Nasdaq

Infinity Pharma (INFI) Stock Up on Advancing Cancer Study

Infinity Pharma INFI announced additional details on the design of its phase II MARIO-8 study, evaluating eganelisib for squamous cell cancer of the head and neck (SCCHN). Shares of the company were ...
FierceBiotech

Infinity Reports Topline Results from Phase 2 Study of Duvelisib in Rheumatoid Arthritis

– Phase 2 Study of Duvelisib with Background Methotrexate in Patients with Moderate-to-Severe Rheumatoid Arthritis Did Not Meet Primary Endpoint – – Infinity to Continue Focusing Its Efforts on the ...
Business Wire

Infiniti’s Market Assessment Study Helped a Medical Implants Supplier Gain 11% Market Share in its New Product Category | Read the Complete Success Story to Gather Detailed ...

LONDON--(BUSINESS WIRE)--Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of its latest success story on market assessment study. This success ...